TransThera: Tinengotinib Solid Tumor Data
12 Apr 2024 //
PR NEWSWIRE
TransThera Announces Phase 3 Completed First Patient Dosing Evaluating Tinengotinib
21 Dec 2023 //
PR NEWSWIRE
TransThera announces an oral presentation of tinengotinib data in breast cancer
07 Dec 2023 //
PR NEWSWIRE
TransThera announces two oral presentations of tinengotinib clinical data
09 Oct 2023 //
PR NEWSWIRE